---
document_datetime: 2024-05-17 14:38:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_en.pdf
document_name: voydeya-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8499455
conversion_datetime: 2025-12-24 03:14:31.809639
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Pack size

| EU/1/24/1792/001   | Voydeya   | 50 mg + 100 mg   | Film-coated tablet   | Oral use   | bottle (HDPE)           | 180 tablets (1 x 90 x 50 mg + 1 x 90 x 100 mg)   |
|--------------------|-----------|------------------|----------------------|------------|-------------------------|--------------------------------------------------|
| EU/1/24/1792/002   | Voydeya   | 50 mg + 100 mg   | Film-coated tablet   | Oral use   | blister (PVC/PCTFE/PVC) | 168 tablets (84 x 50 mg + 84 x 100 mg)           |
| EU/1/24/1792/003   | Voydeya   | 100 mg           | Film-coated tablet   | Oral use   | bottle (HDPE)           | 180 (2 x 90) tablets                             |
| EU/1/24/1792/004   | Voydeya   | 100 mg           | Film-coated tablet   | Oral use   | blister (PVC/PCTFE/PVC) | 168 tablets                                      |